<DOC>
	<DOCNO>NCT01933919</DOCNO>
	<brief_summary>The objective 1st phase randomize study evaluate efficacy SME3110 compare placebo change total score Japanese version Children 's Yale-Brown Obsessive Compulsive Scale 10-item child baseline last observation visit pediatric/adolescent Obsessive Compulsive Disorder subject short-term ( 10 week ) double blind period . The safety SME3110 compare placebo also evaluate . The objective 2nd phase study evaluate long-term safety efficacy SME3110 pediatric/adolescent Obsessive Compulsive Disorder subject .</brief_summary>
	<brief_title>A Phase 3 Study SME3110 Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder</brief_title>
	<detailed_description>The 1st phase conduct randomize , placebo-controlled , double-blind manner evaluate efficacy SME3110 change baseline last observation visit Japanese version Children 's Yale-Brown Obsessive Compulsive Scale 10-item total score . Eligible patient allocate SME3110 group placebo group 1:1 ratio use experience fluvoxamine treatment age stratification factor ( dynamic allocation ) . The 1st phase consist 5 period ; screen period 1-2 week , force titration dose period 2 week , dose adjustment period 4 week , maintain dose period 4 week , taper dose period 0-4 week . The 2nd phase conduct open-label manner patient complete 1st phase evaluate long-term safety SME3110 . The 2nd phase consist 3 period ; force titration dose period 2 week , flexible dose period 50 week , taper dose period 0-4 week . After last dose study drug ( include taper dose period ) early termination visit , subject follow 30 day .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>1 . Subject least 16 score Japanese version Children 's YaleBrown Obsessive Compulsive Scale 10item total score least 5 score Obsession sub total score Compulsion subtotal score respectively Screening period Baseline . 2 . Subject show less 25 % reduction Japanese version Children 's YaleBrown Obsessive Compulsive Scale 10item total score Baseline compare score Screening period ( Total score Baseline ≥ Total score Screening х 0.75 ) . 3 . Subject Obsessive compulsive disorder symptom least 2 month prior inform consent . 4 . Body weight : ≥ standard weight 2 standard deviation base standard weight age School Health Statistical Survey . 5 . Subjects parent legal guardian receive explanation purpose , procedure meaning study sufficiently willing give write informed consent subject . ( possible , write informed assent obtain subject ) . 1 . Subject trichotillomania ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 312.39 ) nailbiting his/her compulsive symptom . 2 . Subject Tourette 's disorder ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 307.23 ) . However , simple motor tic exclude . 3 . Subject diagnose follow psychiatric disorder . Schizophrenia ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 295.xx ) psychotic disorder ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 295.40 [ schizophreniform disorder ] , 295.70 [ schizoaffective disorder ] , 297.1 [ delusional disorder ] , 298.8 [ brief psychotic disorder ] , 297.3 [ share psychotic disorder ] , 293.xx [ psychotic disorder due to… { indicate general medical condition } ] , substance induce psychotic disorder , 298.9 [ psychotic disorder otherwise specify ] ) . Depressive disorder Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 296.xx [ major depressive disorder ] , 296.2x [ single episode ] , 296.3x [ recurrent ] , 300.4 [ dysthymic disorder ] , 311 [ depressive disorder otherwise specify ] ) . Bipolar disorder ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 296.xx [ bipolar I disorder ] , 296.0x [ single manic episode ] , 296.40 [ recent episode hypomanic ] , 296.4x [ recent episode manic ] , 296.6x [ recent episode mixed ] , 296.5x [ recent episode depress ] , 296.7 [ recent episode unspecified ] , 296.89 [ bipolar II disorder ] , 301.13 [ cyclothymic disorder ] , 296.80 [ bipolar disorder otherwise specify ] ) . Mental retardation ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 317 [ mild mental retardation ] , 318.0 [ moderate mental retardation ] , 318.1 [ severe mental retardation ] , 318.2 [ profound mental retardation ] , 319 [ mental retardation , severity unspecified ] ) . Eating disorder ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 307.1 [ anorexia nervosa ] , 307.51 [ bulimia nervosa ] , 307.50 [ eat disorder otherwise specify ] ) . Attentiondeficit/hyperactivity disorder ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 314.xx ) attention deficit/hyperactivity disorder otherwise specify ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 314.9 ) . Obsessive compulsive personality disorder ( Diagnostic Statistical manual Mental Disorders Forth Edition Text Revision : 301.4 ) . Other patient clinical neurological disorder . 4 . Subject diagnose Major Depressive Disorder The MiniInternational Neuropsychiatric Interview Children Adolescents ( A ) Screening period . 5 . Subject treated fluvoxamine within 2 month prior inform consent . Except fluvoxamine dose stable administration period fluvoxamine within 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>Adolescent Subjects</keyword>
	<keyword>Pediatric Subjects</keyword>
</DOC>